divisional applications of national phase entry...

Intellectual Property Center, 28 Upper McKinley Rd. McKinley Hill Town Center, Fort Bonifacio, Taguig City 1634 Philippines

Tel. No. 238-6300 Website: http://www.ipophil.gov.ph e-mail: [email protected]

Volume 20 Number 41 Date Released: April 10, 2017

Divisional Applications of National Phase Entry Applications

1 INVENTION

[19] INTELLECTUAL PROPERTY PHILIPPINES

[12] INVENTION PUBLICATION

[21] Application Number: 1/2015/500485 Document Code:

A1

[86] International Application No.

PCT/GB2012/050457 [22] Int’l Filing Date: 29/02/2012

[87] International Publication No.

WO2012/117246 A1 [43] International Publication Date:

07/09/2012

[85] National Phase Entry Date:

05/03/2015

[60] Division of: 1/2013/501723 filed on 22 August 2013

[54] Title: PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2` - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER

[71] Applicant(s): NUCANA BIOMED LIMITED [GB]

[72] Inventor(s): MCGUIGAN, Christopher[GB]: BALZARINI, Jan[BE]: SLUSARCYZK, Magdalena[PL]: GONCZY, Blanka[HU]: MURZIANI, Paola[IT]

[73] Assignee(s): NONE

[74] Attorney / Agent: SYCIP, SALAZAR, HERNANDEZ AND GATMAITAN

[30] Priority Data: 1103582.1 01/03/2011 GB and 1105660.3 01/04/2011 GB

[51] International Class 8: A 61K 31/675, A 61P 35/00, C 07F 9/6558

[57] Abstract:

Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine are disclosed for use in the treatment of cancer, especially in the treatment of cancer where the patient shows resistance, for example, in a patient with cells with a lowered level of nucleoside transporter proteins and/or with nucleoside kinase-deficient cells and/or with mycoplasma-infected cells and/or with cells with a raised level of thymidylate synthase.

Representative Drawing(s):




Relevant docs:

Category Document description Relevant to claim No.

Document No.

Y WO 99/37753 A1 29 July 1999 (29.07.1999)

1

Y WO 2005/012327 A2 10 February 2005 (10.02.2005)

2







A1


PCT/US2009/040652 [22] Int’l Filing Date: 15/04/2009



22/10/2009


06/03/2015

[60] Division of: 1/2010/502299 filed on 8 October 2010

[54] Title: ORAL PHARMACEUTICAL COMPOSITIONS IN A SOLID DISPERSION COMPRISING PREFERABLY POSACONAZOLE AND HPMCAS

[71] Applicant(s): SCHERING COPRORATION [US]

[72] Inventor(s): FANG, Larry, Yun[US]: HARRIS, David[US]: KRISHNA, Gopal[US]: MOTON, Allen, E., Jr[US]: PRESTIPINO, Russell, C[US]: STEINMAN, Marc[US]: WAN, Jiansheng[US]: WASKIN, Hetty, Anne[US]


[74] Attorney / Agent: HECHANOVA AND CO. INC.

[30] Priority Data: 61/045,177 15/04/2008 US and 61/166,487 03/04/2009 US

[51] International Class 8: A 61K 31/00, 9/16

[57] Abstract:

The present invention provides novel composition comprising posaconazole and a polymer wherein the composition has a glass transition temperature (Tg) of less than about 1100C. The application also describes compositions comprising posaconazole and a polymer having a bulk density of greater than about 0.4 mg/mL. The application also describes compositions comprising posaconazole and a polymer which provide an exposure (AUCtf) of at least about 10,000 ng.hr/mL when administered to a patient in a fasted state. The application also describes a novel process for preparing these compositions. The prefferred polymer is HPMCAS. Preferably the composition is an extruded material.





Relevant docs:


Document No.

X WO 2007/056205 A 18 May 2007 (18.05.2007)

1

X US 2006/062848 A1 23 March 2006 (23.03.2006)

2

X WO 97/44014 A 27 November 1997 (27.11.1997)

3







A1




WO2013/130976 [43] International Publication Date:

06/09/2013


24/07/2015


[54] Title: SERINE/THREONINE KINASE INHIBITORS

[71] Applicant(s): ARRAY BIOPHARMA INC. [US] and GENENTECH, INC [US]

[72] Inventor(s):

BLAKE, James F[US]: CHICARELLI, Mark Joseph[US]: GARREY, Rustam Ferdinand[US]: GAUDINO, John[US]: GRINA, Jonas[US]: MORENO, David A[US]: MOHR, Peter J[US]: REN, Li[US]: SCHWARZ, Jacob[US]: CHEN, Huifen[US]: ROBARGE, Kirk[US]: ZHOU, Aihe[US]


[74] Attorney / Agent: BUCOY POBLADOR & ASSOCIATES

[30] Priority Data: 61/605,523 01/03/2012 US

[51] International Class 8: A 61K 31/435, 31/506, A 61P 29/00, 35/00, C 07D 401/04, 401/14, 405/14, 409/14, 413/14, 417/14, 471/04, C 07F 9/6558, 9/6596

[57] Abstract:

Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Representative Drawing(s): NONE

Relevant docs:

Category Document description Relevant to claim

No.

Document No.

A

WO 01/42241 A1 (MERCK & CO INC [US]; MCINTYRE CHARLES J [US]; LIVERTON NIGEL J [US]; C) 14 June 2001 (14.06.2001)

1




A

WO 2010/077275 A1 (ARENA PHARM INC [US]; TRAN THUY-ANH [US]; HAYASHI RENA [US] IBARRA JA) 08 July 2010 8 July 2010 (08.07.2010)

2

A

WO 03/099808 A1 (AMGEN INC [US]; DOMINGUEZ CELIA [US]; ZHANG DAWEI [US]; CAO GUO-QIANG) 4 December 2003 (04.12.2003)

3

A

WO 2005/123680 A1 (SQUIBB BRISTOL MYERS CO [US]; CORTE JAMES [US]; HANGELAND JON [US]; QU 29 December 2005 (29.12.2005)

4

A

MC INTYRE CJ et al: BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON< ELSIVIER SCIENCE, GB, vol.12, pages 689-692 25 February 2002 (25.02.2002)

5

X

P.STANETTY et al: JOURNAL of ORGANIC CHEMISTRY, vol. 70, no.13, pages 5215-5220 24 June 2005 (24.06.2005)

6







A1




WO2013/130976 [43] International Publication Date:

06/09/2013


24/07/2015


[54] Title: SERINE/THREONINE KINASE INHIBITORS

[71] Applicant(s): ARRAY BIOPHARMA INC. [US] and GENENTECH, INC [US]

[72] Inventor(s):

BLAKE, James F[US]: CHICARELLI, Mark Joseph[US]: GARREY, Rustam Ferdinand[US]: GAUDINO, John[US]: GRINA, Jonas[US]: MORENO, David A[US]: MOHR, Peter J[US]: REN, Li[US]: SCHWARZ, Jacob[US]: CHEN, Huifen[US]: ROBARGE, Kirk[US]: ZHOU, Aihe[US]



[30] Priority Data: 61/605,523 01/03/2012 US

[51] International Class 8: A 61K 31/435, 31/506, A 61P 29/00, 35/00, C 07D 401/04, 401/14, 405/14, 409/14, 413/14, 417/14, 471/04, C 07F 9/6558, 9/6596

[57] Abstract:

Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Representative Drawing(s): NONE

Relevant docs:

Category Document description Relevant to claim

No.

Document No.

A WO 01/42241 A1 14 June 2001 (14.06.2001)

1




A WO 2010/077275 A1 8 July 2010 (08.07.2010)

2

A WO 03/099808 A1 4 December 2003 (04.12.2003)

3

A WO 2005/123680 A1 29 December 2005 (29.12.2005)

4

A

MC INTYRE CJ et al: Bioorganic & Medicinal Chemistry Letters, Pergamon, Elsivier Science, GB, vol. 12 pages 689-692 25 February 2002 (25.02.2002)

5

X P.Stanetty et al: Journal of Organic Chemistry, vol. 70, no. 13, pages 5215-5220

6







A1





29/03/2012


03/09/2015

[60] Division of: 1/2013/500629 filed on 2 April 2013

[54] Title: SUBSTITUTED NUCLEOTIDE ANALOGS

[71] Applicant(s): ALIOS BIOPHARMA, INC. [US]

[72] Inventor(s): SMITH, David, Bernard[US]: DEVAL, Jerome[FR]: DYATKINA, Natalia[US]: BEIGELMAN, Leonid[US]: WANG, Guangyi[US]


[74] Attorney / Agent: ROMULO MABANTA BUENAVENTURA SAYOC & DE LOS ANGLES

[30] Priority Data: 61/385,363 22/09/2010 US and 61/426,461 22/12/2010 US

[51] International Class 8: A 61K 31/7064, 31/7076, 31/708, A 61P 31/12, 31/14, 31/16, C 07F 9/165, C 07H 19/10, 19/20

[57] Abstract:

Disclosed herein are phosphorothioate nucleotide analogs, methods of synthesizing phosphorothioate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphorothioate nucleotide analogs.


Relevant docs:


Document No.

X WO 2007/020018 A1 22 February 2007 (22.02.2007)

1

X WO 2005/020885 A2 10 March 2005 (10.03.2005)

2

X US 2004/0077585 A1 22 April 2004 (22.04.2004)

3




X US 6,004,939 A 21 December 1999 (21.12.1999)

4

X US 5,620,676 A 15 April 1997 (15.04.1997)

5

X DE 4341161 A1 8 June 1995 (08.06.1995)

6

X WO 2006/038865 A1 13 April 2006 (13.04.2006)

7







A1





12/02/2009


22/09/2015

[60] Division of: 1/2010/500230 filed on 27 January 2010

[54] Title: METHOD FOR TREATING DEPENDENCE

[71] Applicant(s): BIOTIE THERAPIES, INC. [US]

[72] Inventor(s): WOIWODE, Tom[US]: MORAN, Mark[US]: PICKFORD, Lesley[US]


[74] Attorney / Agent: ROMULO MABANTA BUENAVENTURA SAYOC AND DELOS ANGELES

[30] Priority Data: 60/935,323 06/08/2007 US; 60/956,555 17/08/2007 US and 60/960,591 04/10/2007 US

[51] International Class 8: A 01N 43/50, A 61K 31/415

[57] Abstract:

Provided are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance with Compound A. Also provided are methods of treating at least one phase of substance dependence on at least one substance in patients and certain methods of treating at least one phase of cocaine dependence in patients.


Relevant docs:


Document No.

Y US 2003/0040015 A1 27 February 2003 (27.02.2003)

1

Y US 2006/0058336 A1 16 March 2006 (16.03.2006)

2

Y US 5,593,367 B1 15 July 2003 (15.07.2003)

3




Y US 5,958,896 A 28 September 1999 (28.09.1999)

4







A1





11/07/2013


06/10/2015

[60] Division of: filed on

[54] Title: DPA-ENRICHED COMPOSITIONS OF OMEGA-3 POLYUNSATURATED FATTY ACIDS IN FREE ACID FORM

[71] Applicant(s): OMTHERA PHARMACEUTICALS INC. [US] and CHRYSALIS PHARMA AG [CH]

[72] Inventor(s): MAINES, Timothy, J[US]: MACHIELSE, Bernardus N M[US]: MEHTA, Bharat M[US]: WISLER, Gerald[US]: DAVIDSON, Michael[US]: WOOD, Peter Ralph[GB]


[74] Attorney / Agent: ORBOS, CABUSORA & TAGUIAM

[30] Priority Data: 61/583,796 06/01/2012 US; 61/664,047 25/06/2012 US; 61/669,940 10/07/2012 US; 61/680,622 07/08/2012 US; 61/710,517 05/10/2012 US and 61/713,388 12/10/2012 US

[51] International Class 8: A 61K 31/19, A 61P 9/00

[57] Abstract:

DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented. Also provided are methods of treating hypertriglyceridemia (200 mg/dL - 500 mg/dL) by adjunctive administration of a statin and the pharmaceutical compositions described herein. Further treatment methods include, inter alia, treatments to increase plasma EPA:AA ratios, treatments to decrease ApoCIII levels, and treatments to reduce or prevent resistance to platelet aggregation inhibitors.





Relevant docs:


Document No.

X US 5,502,077 A 26 March 1996 (26.03.1996)

1

Y US 2011/0034555 A1 10 February 2011 (10.02.2011)

2

Y US 2011/0097394 A1 28 April 2011 (28.04.2011)

3







A1


PCT/EP2013/054606 [22] Int’l Filing Date: 07/03/2013



12/09/2013


09/11/2015


[54] Title: HUMAN BINDING MOLECULES CAPABLE OF BINDING TO AND NEUTRALIZING INFLUENZA B VIRUSES AND USES THEREOF

[71] Applicant(s): CRUCELL HOLLAND B.V. [NL]

[72] Inventor(s): KWAKS, Theodorus Hendrikus Jacobus[NL]: VOGELS, Ronald[NL]



[30] Priority Data: 12158525.1 08/03/2012 EP and 61/608,414 08/03/2012 US

[51] International Class 8: C 07K 16/10

[57] Abstract:

The present invention relates to binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. The binding molecules do not bind to hemagglutinin of influenza A viruses. The invention further provides nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of influenza B viruses.





Relevant docs:


Document No.

Y WO 2010/130636 A1 18 November 2010 (18.11.2010)

1

A WO 2009/002380 A2 31 December 2008 (31.12.2008)

2

A US 2010/330103 A1 30 December 2010 (30.12.2010)

3







A1


PCT/IB2013/055434 [22] Int’l Filing Date: 02/07/2013



09/01/2014


22/01/2016

[60] Division of: 1/2014/502865 filed on 22 December 2014

[54] Title: SELECTIVE PI3K DELTA INHIBITORS

[71] Applicant(s): RHIZEN PHARMACEUTICALS SA [CH]

[72] Inventor(s): VAKKALANKA, Swaroop Kumar Venkata Satya[CH]: MUTHUPPALANIAPPAN, Meyyappan[IN]: NAGARATHNAM, Dhanapalan[CH]


[74] Attorney / Agent: ORTEGA BACORRO ODULIO CALMA AND CARBONELL

[30] Priority Data: 2692/CHE/2012 04/07/2012 IN; 2693/CHE/2012 04/07/2012 IN; 61/691,561 21/08/2012 US and 61/691,586 21/08/2012 US

[51] International Class 8: A 61K 31/519, A 61P 35/00, C 07D 487/04

[57] Abstract:

The present invention relates to selective inhibitors of PI3K delta protein kinases having a 1H-pyrazolo[3,4-d]pyrimidine ring system, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.


Relevant docs:


Document No.

X WO 2011/055215 A2 12 May 2011 (12.05.2011)

1

A WO 2010/111432 A1 30 September 2010 (30.09.2010)

2







A1


PCT/KR2013/002378 [22] Int’l Filing Date: 22/03/2013



03/10/2013


03/03/2016


[54] Title: PHARMACEUTICAL COMPOSITION COMPRISING OLMESARTAN MEDOXOMIL AND ROSUVASTATIN OR ITS SALT

[71] Applicant(s): DAEWOONG PHARMACEUTICAL CO., LTD. [KR]

[72] Inventor(s): CHANG, Hee-Chul[KR]: KANG, Bok-Ki[KR]: KIM, Jun-Ku[KR]


[74] Attorney / Agent: A.Q. ANCHETA AND PARTNERS

[30] Priority Data: 10-2012-0032903 30/03/2012 KR

[51] International Class 8: A 61K 31/4178, 31/505, 9/20, 9/48

[57] Abstract:

The present invention provides a pharmaceutical composition having a single dosage form comprising a compartment comprising olmesartan medoxomil; and a compartment comprising rosuvastatin or its salt, wherein said compartments are formulated in a separate form. In the pharmaceutical composition of the present invention, olmesartan medoxomil and rosuvastatin or its salt are formulated into a combination dosage form having separate compartments, thereby being able to solve the absorption-inhibition problem originated from drug interaction. In addition, the use of a certain disintegrant(s) makes it possible to obtain a combination formulation bioequivalent to the single formulation of each of drugs.


Relevant docs:


Document No.

X WO 2008-068217 A2 12 June 2008 (12.06.2008)

1




X US 2011-0212175 A1 01 September 2011 (01.09.2011)

2

X US 2011-0217374 A1 08 September 2011 (08.09.2011)

3

A WO 2009-154810 A2 23 December 2009 (23.12.2009)

4

A WO 2011-107750 A2 09 September 2011 (09.09.2011)

5







A1


PCT/GB2013/051606 [22] Int’l Filing Date: 20/06/2013



27/12/2013


14/03/2016


[54] Title: CAMSYLATE SALT

[71] Applicant(s): ASTRAZENECA AB [SE]

[72] Inventor(s): BOHLIN, Martin, Hans[GB]: STEWART, Craig Robert[GB]


[74] Attorney / Agent: ORBOS CABUSORA AND TAGUIAM LAW OFFICE

[30] Priority Data: 61/662,592 21/06/2012 US

[51] International Class 8: A 61K 31/4439, A 61P 25/28, C 07D 401/10

[57] Abstract:

A camsylate salt of (1r,1 'R,4R)- 4-methoxy-5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-inden-1'2'-imidazole]-4"-amine, pharmaceutical compositions containing the salt and therapeutic uses of the salt for treating ?ß-related pathologies such as Alzheimer's Disease, Down's syndrome, ß-amyloid angiopathy and conditions such as dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.


Relevant docs:


Document No.

A WO 2011/002408 A1 6 January 2011 (06.01.2011)

1

A WO 2012/087237 A1 28 June 2012 (28.06.2012)

2







A1





19/11/2009


15/04/2016

[60] Division of: 1/2010/502555 filed on 12 November 2010

[54] Title: METHOD OF TREATING DYSPNEA ASSOCIATED WITH ACUTE HEART FAILURE

[71] Applicant(s): CORTHERA, INC. [US]

[72] Inventor(s): UNEMORI, Elaine[US]: TEICHMAN, Sam, L.[US]: COTTER, Gad[IL]: STEWART, Dennis, R[US]: WHITEHOUSE, Martha, Jo[US]


[74] Attorney / Agent: E.B. ASTUDILLO AND ASSOCIATES

[30] Priority Data: 61/127,889 16/05/2008 US; 61/164,333 27/03/2009 US; 61/190,545 28/08/2012 US and 61/201,240 08/12/2008 US

[51] International Class 8: A 61K 38/22, A 61P 9/04, C 07K 14/64

[57] Abstract:

The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.


Relevant docs:


Document No.

X US 2007/202080 A1 30 August 2007 (30.08.2007)

1

X US 5,166,191 A 24 November 1992 (24.11.1992)

2

X WO 02/40500 A2 23 May 2002 (23.05.2002)

3







A1


PCT/JP 2012/007095 [22] Int’l Filing Date: 06/11/2012


WO 2013/069255 A1 [43] International Publication Date:

16/05/2013


13/12/2016


[54] Title: IMAGE CODING METHOD, IMAGE CODING APPARATUS, IMAGE DECODING METHOD AND IMAGE DECODING APPARATUS

[71] Applicant(s): TAGIVAN II LLC [JP]

[72] Inventor(s): SASAI, Hisao[JP]: NISHI, Takahiro[JP]: SHIBAHARA, Youji[JP]: SUGIO, Toshiyasu[JP]: TANIKAWA, Kyoko[JP]: MATSUNOBU, Toru[JP]: TERADA, Kengo[JP]


[74] Attorney / Agent: ROMULO MABANTA BUENAVENTURA SAYOC AND DELOS ANGELES

[30] Priority Data: 61/556,398 07/11/2011 US

[51] International Class 8: H 04N 19/46, 19/91, 7/00, 7/26

[57] Abstract:

An image encoding method comprising: a binarization step (S401) in which the LAST position information is binarized to generate either (i) a binarized signal which includes a first signal having a length equal to or shorter than a predetermined maximum length and which does not include a second signal, or (ii) a binarized signal which includes a first signal having a predetermined maximum length and a second signal; a first encoding step (S402) in which the context for each binary symbol in the first signal is switched according to the bit position of the binary symbol, and the binary symbols are arithmetically encoded; and a second encoding step (S404) in which if the binarized signal includes a second signal, the second signal is arithmetically encoded using a fixed probability. In the first encoding step, if the first signal has the predetermined maximum length, the binary symbol at the final bit position in the first signal is arithmetically encoded using a context exclusive to the final bit position.





Relevant docs:


Document No.

X US 7,292,731 B2 - SHUNICHI SEKIGUCHI, ET. AL. - 6 November 2007

1

X US 8,594,366 B2 - DEKUN ZOU, ET. AL. - 26 November 2013

2

X US 8,938,010 B2 - THOMAS STOCKHAMMER - 20 January 2015

3

divisional applications of national phase entry...

Documents